Nifty
Sensex
:
:
11504.95
38845.82
-11.15 (-0.10%)
-134.03 (-0.34%)

Pharmaceuticals & Drugs - Global

Rating :
72/99

BSE: 532523 | NSE: BIOCON

454.00
18-Sep-2020
  • Open
  • High
  • Low
  • Previous Close
  •  442.75
  •  463.90
  •  442.75
  •  442.20
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  11410425
  •  51865.30
  •  463.90
  •  212.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 53,052.00
  • 76.74
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 54,678.80
  • N/A
  • 7.84

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.67%
  • 1.03%
  • 10.55%
  • FII
  • DII
  • Others
  • 15.93%
  • 5.41%
  • 6.41%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.43
  • 13.72
  • 15.58

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -5.97
  • 10.36
  • 8.68

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.78
  • 8.01
  • 30.32

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 23.17
  • 38.76
  • 53.50

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.19
  • 5.16
  • 6.13

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.51
  • 23.18
  • 27.59

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
1,671.30
1,465.90
14.01%
1,581.00
1,528.80
3.41%
1,748.10
1,540.80
13.45%
1,572.20
1,321.00
19.02%
Expenses
1,258.00
1,028.40
22.33%
1,262.40
1,125.80
12.13%
1,303.90
1,160.10
12.40%
1,169.40
981.40
19.16%
EBITDA
413.30
437.50
-5.53%
318.60
403.00
-20.94%
444.20
380.70
16.68%
402.80
339.60
18.61%
EBIDTM
24.73%
29.85%
14.01%
26.36%
25.41%
24.71%
25.62%
25.71%
Other Income
18.30
24.10
-24.07%
63.10
28.20
123.76%
35.80
25.60
39.84%
38.40
54.40
-29.41%
Interest
12.50
16.60
-24.70%
16.80
15.90
5.66%
17.70
18.60
-4.84%
13.80
18.80
-26.60%
Depreciation
166.80
124.20
34.30%
152.40
119.80
27.21%
144.00
116.70
23.39%
131.60
112.20
17.29%
PBT
252.30
320.80
-21.35%
212.50
295.50
-28.09%
318.30
276.80
14.99%
363.30
451.80
-19.59%
Tax
80.90
85.20
-5.05%
45.00
40.90
10.02%
84.80
46.10
83.95%
100.10
73.20
36.75%
PAT
171.40
235.60
-27.25%
167.50
254.60
-34.21%
233.50
230.70
1.21%
263.20
378.60
-30.48%
PATM
10.26%
16.07%
7.11%
16.65%
13.36%
14.97%
16.74%
28.66%
EPS
1.43
1.96
-27.04%
1.40
2.12
-33.96%
1.95
1.92
1.56%
2.19
3.16
-30.70%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
6,572.60
6,367.20
5,514.40
4,123.40
3,891.10
3,347.40
3,089.80
2,877.30
2,485.30
2,086.50
1,806.00
Net Sales Growth
12.23%
15.46%
33.73%
5.97%
16.24%
8.34%
7.39%
15.77%
19.11%
15.53%
 
Cost Of Goods Sold
6,240.90
2,052.20
1,896.60
1,636.10
1,446.60
1,290.40
1,255.60
1,186.10
1,044.40
852.00
725.40
Gross Profit
331.70
4,315.00
3,617.80
2,487.30
2,444.50
2,057.00
1,834.20
1,691.20
1,440.90
1,234.50
1,080.60
GP Margin
5.05%
67.77%
65.61%
60.32%
62.82%
61.45%
59.36%
58.78%
57.98%
59.17%
59.83%
Total Expenditure
4,993.70
5,110.20
4,120.70
3,294.30
2,911.60
2,579.60
2,394.00
2,190.20
1,946.30
1,809.30
2,213.40
Power & Fuel Cost
-
246.10
239.80
189.00
156.40
184.70
176.70
162.40
142.60
97.20
82.00
% Of Sales
-
3.87%
4.35%
4.58%
4.02%
5.52%
5.72%
5.64%
5.74%
4.66%
4.54%
Employee Cost
-
1,458.80
1,165.30
931.10
747.00
610.10
533.40
466.30
389.40
307.60
238.80
% Of Sales
-
22.91%
21.13%
22.58%
19.20%
18.23%
17.26%
16.21%
15.67%
14.74%
13.22%
Manufacturing Exp.
-
864.60
451.30
335.70
391.50
203.70
81.20
62.90
95.20
113.20
81.60
% Of Sales
-
13.58%
8.18%
8.14%
10.06%
6.09%
2.63%
2.19%
3.83%
5.43%
4.52%
General & Admin Exp.
-
182.10
53.00
56.80
21.70
144.60
165.70
131.80
122.20
93.20
82.40
% Of Sales
-
2.86%
0.96%
1.38%
0.56%
4.32%
5.36%
4.58%
4.92%
4.47%
4.56%
Selling & Distn. Exp.
-
270.30
277.50
98.20
107.40
100.80
108.70
118.90
99.60
89.40
62.40
% Of Sales
-
4.25%
5.03%
2.38%
2.76%
3.01%
3.52%
4.13%
4.01%
4.28%
3.46%
Miscellaneous Exp.
-
36.10
37.20
47.40
41.00
45.30
72.70
61.80
52.90
256.70
62.40
% Of Sales
-
0.57%
0.67%
1.15%
1.05%
1.35%
2.35%
2.15%
2.13%
12.30%
52.09%
EBITDA
1,578.90
1,257.00
1,393.70
829.10
979.50
767.80
695.80
687.10
539.00
277.20
-407.40
EBITDA Margin
24.02%
19.74%
25.27%
20.11%
25.17%
22.94%
22.52%
23.88%
21.69%
13.29%
-22.56%
Other Income
155.60
507.50
144.40
206.20
157.10
79.20
53.10
55.90
56.70
309.40
1,035.50
Interest
60.80
64.90
70.90
61.50
26.00
29.30
8.90
1.70
8.10
12.40
24.30
Depreciation
594.80
552.20
447.80
385.10
277.20
248.70
221.00
203.60
179.30
175.80
156.70
PBT
1,146.40
1,147.40
1,019.40
588.70
833.40
569.00
519.00
537.70
408.30
398.40
447.10
Tax
310.80
315.10
212.30
156.90
161.60
142.20
95.70
106.90
97.50
55.90
72.10
Tax Rate
27.11%
25.94%
17.49%
26.65%
19.39%
19.49%
15.33%
19.88%
15.98%
14.03%
16.13%
PAT
835.60
777.10
904.40
351.10
595.80
528.70
497.40
413.80
508.90
341.60
367.50
PAT before Minority Interest
751.60
899.80
1,001.70
431.80
671.80
587.40
528.40
430.80
512.70
342.50
375.00
Minority Interest
-84.00
-122.70
-97.30
-80.70
-76.00
-58.70
-31.00
-17.00
-3.80
-0.90
-7.50
PAT Margin
12.71%
12.20%
16.40%
8.51%
15.31%
15.79%
16.10%
14.38%
20.48%
16.37%
20.35%
PAT Growth
-24.00%
-14.08%
157.59%
-41.07%
12.69%
6.29%
20.20%
-18.69%
48.98%
-7.05%
 
EPS
6.96
6.48
7.54
2.93
4.97
4.41
4.15
3.45
4.24
2.85
3.06

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
6,705.80
6,098.00
5,180.80
4,837.70
4,033.80
3,270.60
3,026.70
2,694.60
2,272.40
2,032.80
Share Capital
600.00
300.00
300.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
Total Reserves
5,997.00
5,720.80
4,812.30
4,670.20
3,933.80
3,132.70
2,806.20
2,491.80
2,079.80
1,850.50
Non-Current Liabilities
2,684.70
2,123.20
2,006.50
2,304.60
2,421.30
1,377.90
1,262.00
666.30
645.20
455.50
Secured Loans
1,220.80
1,539.50
1,787.00
2,104.30
2,061.00
758.20
580.40
124.00
9.30
0.00
Unsecured Loans
1.40
2.10
2.80
3.90
11.40
11.40
25.80
40.00
60.50
65.80
Long Term Provisions
85.80
66.10
49.30
36.00
29.90
15.00
7.80
4.00
0.00
1.00
Current Liabilities
4,008.00
3,037.60
2,141.30
1,678.30
1,665.70
1,554.70
1,379.60
989.90
1,015.80
1,060.60
Trade Payables
1,325.10
1,198.30
1,005.30
739.70
609.80
429.30
347.20
345.50
347.80
296.50
Other Current Liabilities
1,784.40
1,373.80
870.10
698.20
527.10
706.20
612.30
313.10
269.20
375.90
Short Term Borrowings
667.60
261.20
130.30
97.20
394.90
261.00
243.50
84.80
187.30
247.40
Short Term Provisions
230.90
204.30
135.60
143.20
133.90
158.20
176.60
246.50
211.50
140.80
Total Liabilities
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
Net Block
5,971.10
4,471.00
3,699.50
3,625.10
1,748.30
1,629.90
1,525.20
1,510.30
1,270.50
1,316.20
Gross Block
9,147.40
7,095.00
5,873.80
5,436.10
3,403.60
3,034.20
2,701.70
2,480.90
2,066.20
1,965.80
Accumulated Depreciation
3,176.30
2,624.00
2,174.30
1,811.00
1,655.30
1,404.30
1,176.50
970.60
795.70
649.60
Non Current Assets
8,750.80
7,044.90
5,647.70
5,149.00
4,415.70
3,812.80
3,111.80
2,176.10
1,937.50
1,779.40
Capital Work in Progress
2,196.00
1,898.90
1,302.80
839.20
2,239.50
1,676.40
1,205.60
312.50
389.50
262.10
Non Current Investment
108.50
182.50
63.80
188.80
26.80
0.00
64.50
64.50
64.20
60.90
Long Term Loans & Adv.
402.00
401.50
437.20
319.70
350.10
336.90
252.00
241.60
181.00
140.20
Other Non Current Assets
73.20
91.00
144.40
176.20
51.00
169.60
64.50
47.20
32.30
0.00
Current Assets
5,325.00
4,822.80
4,148.60
4,047.70
3,970.90
2,562.60
2,638.80
2,240.00
1,999.70
1,807.20
Current Investments
857.60
829.30
611.40
1,065.00
874.70
230.30
700.40
522.10
492.10
399.50
Inventories
1,435.90
1,031.60
722.50
635.30
542.40
452.70
376.60
398.40
378.30
413.70
Sundry Debtors
1,223.70
1,291.80
1,063.90
883.20
714.50
770.50
599.80
509.70
491.70
495.80
Cash & Bank
998.60
1,057.20
1,322.80
1,044.30
1,538.60
937.50
804.40
672.90
523.30
441.50
Other Current Assets
809.20
566.50
373.30
395.80
300.70
171.60
157.60
136.90
114.30
56.70
Short Term Loans & Adv.
265.60
46.40
54.70
24.10
227.10
75.80
81.80
81.40
37.10
20.20
Net Current Assets
1,317.00
1,785.20
2,007.30
2,369.40
2,305.20
1,007.90
1,259.20
1,250.10
983.90
746.60
Total Assets
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
1,283.10
1,154.60
662.10
640.00
370.60
210.70
560.70
471.20
564.10
798.50
PBT
870.90
1,214.90
610.00
849.70
751.30
624.10
537.70
610.20
395.20
447.10
Adjustment
921.40
260.30
355.70
204.40
42.00
74.00
134.00
147.30
144.80
163.50
Changes in Working Capital
-165.10
-29.10
-106.50
-211.10
-176.20
-354.00
37.70
-192.30
98.00
269.20
Cash after chg. in Working capital
1,627.20
1,446.10
859.20
843.00
617.10
344.10
709.40
565.20
638.00
879.80
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-344.10
-291.50
-197.10
-203.00
-246.50
-133.40
-148.70
-94.00
-73.90
-81.30
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,558.90
-713.80
-684.00
-498.50
-1,141.70
-508.70
-938.10
-375.80
-359.50
-314.50
Net Fixed Assets
744.40
-280.60
-177.90
-215.90
-216.90
-57.90
-322.80
-213.80
-75.20
-134.97
Net Investments
-967.20
184.70
-310.70
-79.30
-3,688.10
328.50
125.80
38.00
-171.10
-67.26
Others
-1,336.10
-617.90
-195.40
-203.30
2,763.30
-779.30
-741.10
-200.00
-113.20
-112.27
Cash from Financing Activity
387.60
-241.70
-239.70
-177.50
1,067.60
186.20
426.00
-8.60
-186.30
-274.60
Net Cash Inflow / Outflow
111.80
199.10
-261.60
-36.00
296.50
-111.80
48.60
86.80
18.30
209.40
Opening Cash & Equivalents
659.30
449.00
710.20
757.50
457.50
557.00
474.00
369.00
359.00
139.90
Closing Cash & Equivalent
824.70
659.30
449.00
710.20
757.50
462.60
557.00
474.00
369.00
359.00

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
54.97
50.17
42.59
39.74
33.61
26.93
24.21
21.59
18.16
16.25
ROA
6.94%
9.25%
4.55%
7.64%
7.96%
8.72%
8.47%
12.28%
9.10%
11.50%
ROE
14.26%
18.00%
8.74%
15.26%
16.17%
17.22%
15.68%
21.50%
16.59%
20.58%
ROCE
14.35%
16.10%
8.92%
12.59%
13.93%
15.30%
15.75%
22.47%
16.74%
20.33%
Fixed Asset Turnover
0.78
0.85
0.73
0.89
1.05
1.09
1.12
1.11
1.06
0.97
Receivable days
72.10
77.96
86.05
74.35
80.16
80.09
69.48
72.22
84.37
93.20
Inventory Days
70.72
58.05
60.00
54.81
53.71
48.47
48.54
56.01
67.67
77.71
Payable days
80.65
86.75
87.98
78.68
71.28
58.15
55.73
65.24
70.25
70.62
Cash Conversion Cycle
62.18
49.26
58.07
50.48
62.59
70.42
62.29
62.99
81.79
100.29
Total Debt/Equity
0.40
0.40
0.44
0.48
0.61
0.35
0.30
0.10
0.12
0.17
Interest Cover
19.72
18.12
10.57
33.05
25.90
71.12
317.29
76.33
33.13
19.40

News Update:


  • Biocon’s arm allots equity shares to Tata Capital Growth Fund II
    4th Sep 2020, 10:44 AM

    The company has received approval from board for the allotment of 88 30,456 equity shares of Rs 10 each

    Read More
  • Biocon’s arm, Mylan launch Semglee in US
    1st Sep 2020, 09:15 AM

    Semglee has an identical amino acid sequence to Sanofi’s Lantus and is approved for the same indications

    Read More
  • Tata Capital to invest in Biocon’s arm
    31st Jul 2020, 10:24 AM

    Tata Capital will invest Rs 225 crore for a 0.85% minority stake in the biosimilar business

    Read More
  • Biocon reports 29% fall in Q1 consolidated net profit
    24th Jul 2020, 14:20 PM

    Total income of the company increased by 13.93% at Rs 1689.60 crore for Q1FY21

    Read More
  • Biocon - Quarterly Results
    23rd Jul 2020, 23:05 PM

    Read More
  • Biocon’s arm collaborates with Voluntis to develop, distribute innovative digital therapeutics
    21st Jul 2020, 09:46 AM

    Insulia provides automated insulin dose recommendations enabling people with diabetes to self-manage their condition and healthcare teams to remotely monitor progress

    Read More
  • Biocon gets DCGI’s nod to market Itolizumab Injection
    13th Jul 2020, 08:57 AM

    Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe COVID-19 complications

    Read More
  • Biocon to invest Rs 1,500 crore on capital expenditure in FY21
    3rd Jul 2020, 09:44 AM

    The company's capital expenditure stood at Rs 974.2 crore during 2019-20

    Read More
  • Biocon’s arm, DKSH collaborate to commercialize seven generic formulations in South East Asia markets
    22nd Jun 2020, 09:33 AM

    This development is in line with Biocon’s strategy for expansion of its generic formulations business through licensing of its drug products in multiple markets

    Read More
  • Biocon, Mylan get USFDA’s approval for insulin glargine injection ‘Semglee’
    12th Jun 2020, 09:03 AM

    Semglee has an identical amino acid sequence to Sanofi’s Lantus and is approved for the same indications

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.